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 Strategies for Trypanosoma brucei gambiense elimination 
Human African trypanosomiasis, a disease caused 
by Trypanosoma brucei (T b) gambiense, is endemic 
in 24 countries across sub-Saharan Africa, aﬀ ecting 
disproportionately the most impoverished regions, 
including the Democratic Republic of Congo and 
Central African Republic.1 Since the early 1990s, 
concerted control eﬀ orts have achieved a steady 
decline in incidence. This success has spurred WHO’s 
goal to eliminate human African trypanosomiasis 
caused by T b gambiense as a public health problem by 
2020, deﬁ ned as reducing reported cases to fewer than 
one per 10 000 inhabitants in at least 90% of settings, 
with fewer than 2000 cases annually in Africa.2 The 
subsequent goal of WHO is to eliminate any reported 
cases of human African trypanosomiasis caused by 
T b gambiense in endemic countries by 2030, thereby 
terminating transmission of the disease globally. 
To facilitate WHO’s goals, it is important to 
assess the cost-eﬀ ectiveness of interventions that 
incorporate emerging technologies for case detection, 
treatment, and vector control in the context of 
economic constraints and logistical barriers. In an 
elegant modelling study in The Lancet Global Health, 
Simone Sutherland and colleagues evaluated the 
cost-eﬀ ectiveness of synergistic and progressively 
available approaches.3 To account for heterogeneity 
in tsetse exposure and the role of animal reservoirs, 
strategies were investigated in the context of varying 
disease dynamics and transmission intensities that 
characterise a range of settings. Their analyses indicated 
that, although several strategy combinations have the 
potential to achieve elimination goals, only approaches 
that incorporate emerging diagnostic, treatment, 
and vector control technologies are cost-eﬀ ective. 
More speciﬁ cally, their ﬁ ndings suggested that current 
control methods comprised exclusively of passive and 
active case-ﬁ nding followed by treatment are not cost-
eﬀ ective options relative to strategies that include 
vector control with improved insecticide-impregnated 
screens, mobile teams with rapid diagnostic methods, 
and next-generation treatment regimens. 
Over the past decade, the incidence of human 
African trypanosomiasis caused by T b gambiense 
has dropped by more than 75%, down to fewer than 
4000 reported cases a year. Nonetheless, an estimated 
70 million people across 35 countries remain at risk of 
T b gambiense infection, and incidence is thought to be 
widely under-reported. Among regions at risk of human 
African trypanosomiasis caused by T b gambiense, 62% 
are currently low transmission areas.4 Sutherland and 
colleagues found that strategies most likely to meet 
elimination goals are not cost-eﬀ ective in areas of low 
transmission, highlighting the eﬀ ect of variations in 
transmission intensities across settings on the cost-
eﬀ ectiveness of control eﬀ orts. Heterogeneity in 
incidence between settings arises from variable tsetse 
density, distributions in human exposure to tsetse, 
animal reservoirs, compliance with active screening, and 
under-reporting. The eﬀ ect of variation in these factors 
should be considered with respect to the optimality of 
alternative strategies in speciﬁ c settings. For example, 
strategies most likely to achieve elimination in areas 
such as Bipindi, Cameroon, where livestock are an 
important disease reservoir,5 might be diﬀ erent in 
settings including Boﬀ a, Guinea, where livestock have a 
small role.6 As a result, the cost-eﬀ ectiveness of tailored 
and localised recommendations will have greater use 
in facilitating elimination than will broad guidance. 
We should also bear in mind that, as incidence declines, 
handling of remaining cases becomes disproportionately 
costly and challenging. Further studies that capture 
the long-term beneﬁ ts of eradication, including the 
reduced monetary commitment and, most importantly, 
averted health burden for future generations, will be 
fundamental to assessing the indirect beneﬁ ts and 
the positive externalities of achieving and sustaining 
elimination. 
Progress towards WHO’s goals for 2020 and 2030 
must be paralleled with a shift in focus towards 
identifying optimum control strategies to maintain 
elimination, as shown by the history of control 
eﬀ orts for human African trypanosomiasis caused 
by T b gambiense. Through a combination of vector 
control and active and passive case-ﬁ nding for early 
detection and rapid treatment of cases, human African 
trypanosomiasis caused by T b gambiense was near 
eradicated in the early 1960s. Unfortunately, a collapse 
of surveillance and monitoring activities in endemic 
countries, primarily originating from political instability, 
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1990s.7 The cost-eﬀ ectiveness framework developed 
by Sutherland and colleagues for human African 
trypanosomiasis is a powerful method for informing 
a more eﬀ ective endgame strategy. For example, to 
mitigate the possibility of resurgence, evaluation of the 
cost-eﬀ ectiveness of surveillance methods to maintain 
elimination status across settings and assessment of 
the value of dedicating resources for post-elimination 
eﬀ orts will be important. 
Despite impressive progress towards elimination, 
social unrest, gaps in the coverage of populations at 
risk, competing health interests, and possible donor 
fatigue present challenges to successful elimination of 
human African trypanosomiasis caused by T b gambiense 
and subsequent maintenance of this status. The timely 
ﬁ ndings of Sutherland and colleagues show the value of 
adopting new control methods for diagnosis, treatment, 
and surveillance that are expected to accelerate 
elimination cost-eﬀ ectively, in a range of settings. 
Translation of these ﬁ ndings into ﬁ eld implementation 
will require continued awareness and commitment 
among governments and key players in global public 
health, until 2030 and beyond. 
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